Deciphering the Therapeutic Mechanisms of XXLP in Ulcerative Colitis via NOX2/ROS/Mitochondria/NLRP3 Axis Regulation

Study Background and Research Question

Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease characterized by mucosal immune dysregulation, oxidative stress, and gut microbiota disturbances. Despite the availability of pharmacological interventions—such as aminosalicylates, corticosteroids, and immunosuppressants—many patients experience insufficient symptom control, adverse effects, or high economic burden. This has spurred significant interest in evidence-based complementary therapies, particularly those rooted in traditional Chinese medicine.

Xu Chunfu’s Modified Xianglian Pill (XXLP) is a classical herbal formulation historically used to treat symptoms analogous to modern UC. However, the molecular mechanisms underlying its clinical efficacy have not been well elucidated. The present study (Mao et al., 2026) addresses this gap by investigating how XXLP modulates the NOX2/ROS/mitochondria/NLRP3 signaling axis and gut microbiota to attenuate colitis.

Key Innovation from the Reference Study

The principal innovation lies in the comprehensive mechanistic dissection linking XXLP’s therapeutic effects to the suppression of NOX2-mediated reactive oxygen species (ROS) generation, mitochondrial dysfunction, and downstream NLRP3 inflammasome activation. By combining advanced proteomics, molecular docking, and multiple validation modalities, the study identifies NADPH oxidase 2 (NOX2) as a pivotal target, connecting redox imbalance to inflammatory and microbiota-related pathologies in UC. This integrative approach bridges traditional herbal pharmacology with contemporary molecular and cellular insights.

Methods and Experimental Design Insights

The research team adopted a multi-tiered experimental design:

• Chemical Profiling: Ultra-performance liquid chromatography coupled to electrospray ionization tandem mass spectrometry (UPLC-ESI-MS/MS) was employed to characterize XXLP’s phytochemical composition, revealing 373 distinct compounds.
• In Vivo Disease Modeling: A dextran sulfate sodium (DSS)-induced mouse colitis model was established to simulate UC’s inflammatory pathology. Disease severity was assessed through body weight monitoring, disease activity index (DAI), colon length measurement, and histopathological scoring.
• Inflammatory Marker Assessment: Cytokine concentrations (IL-1β, IL-18, TNF-α, and IL-6) were quantified via enzyme-linked immunosorbent assay (ELISA).
• Proteomics and Target Elucidation: Mass spectrometry-based proteomics and in silico molecular docking identified NOX2 as a central node affected by XXLP.
• Validation in Cell Lines: LPS-induced HT-29 human colon epithelial cells were used for independent confirmation with quantitative real-time PCR (qRT-PCR), Western blot (WB), immunofluorescence (IF), and transmission electron microscopy (TEM).
• Microbiota Analysis: 16S rRNA gene sequencing profiled gut microbial shifts in response to XXLP.

Protocol Parameters

• DSS-induced colitis: Mice received 2–3% DSS in drinking water for 7 days to induce colitis symptoms, followed by XXLP treatment.
• XXLP dosing: Administered orally at a concentration determined by body weight; dosing schedules and duration matched historical decoction practices (see reference study).
• Inflammatory marker measurement: Serum and colon tissue harvested post-treatment; ELISA performed according to manufacturer’s protocols.
• Cellular validation: HT-29 cells pre-treated with XXLP extract, then challenged with LPS at 1 μg/mL to induce inflammatory signaling.
• Microbiota sequencing: Fecal samples collected at endpoint; 16S rRNA gene V3–V4 region amplified and sequenced.

Core Findings and Why They Matter

The study’s findings establish a mechanistic framework for XXLP’s efficacy in colitis:

• Alleviation of Colitis Phenotypes: XXLP intervention led to significant improvements in body weight, disease activity index, colon length, and histopathology scores (Mao et al., 2026).
• Suppression of Inflammatory Cytokines: Levels of IL-1β, IL-18, TNF-α, and IL-6 were markedly reduced in both serum and colonic tissue, underscoring potent anti-inflammatory activity.
• Targeted Downregulation of NOX2: Proteomics, docking, and validation in LPS-induced HT-29 cells demonstrated that XXLP specifically downregulates NOX2 and associated subunits, thereby disrupting the NOX2/ROS/mitochondria/NLRP3 positive feedback loop.
• Mitochondrial Protection: TEM and IF analyses confirmed that XXLP preserves mitochondrial integrity, likely mitigating further ROS production and inflammasome activation.
• Microbiota Remodeling: 16S rRNA sequencing revealed increased abundance of beneficial bacteria (e.g., Muribaculaceae, Ruminococcaceae) and decreased pathogenic taxa (e.g., Enterobacteriaceae), suggesting a dual role in immune modulation and barrier function.
• Correlative Evidence: Specific microbiota changes correlated with NOX2-related protein levels and colitis severity, implicating a bidirectional relationship between redox signaling and gut ecology.

This integrated mechanism positions XXLP as a promising candidate for multi-targeted intervention in UC, bridging redox biology, immunology, and microbiome research.

Comparison with Existing Internal Articles

Recent internal resources corroborate and contextualize these findings. For example, an article on the mechanistic action of XXLP highlights its regulation of the NOX2/ROS/mitochondria/NLRP3 axis, echoing the present study’s conclusion that targeting oxidative stress and inflammasome pathways is central to mitigating intestinal inflammation. Additionally, advances in energy metabolism assays—such as those described in the Luminescent ATP Detection Assay Kit overview—underscore the importance of robust, sensitive techniques for quantifying cellular ATP as a readout of mitochondrial function in disease models.

Notably, the reference study’s focus on mitochondrial integrity and oxidative signaling aligns with workflows that employ firefly luciferase ATP assays for cellular ATP quantification, as discussed in reliability-focused technical guides. Together, these resources illustrate a convergent trend: leveraging precise biochemical assays and integrative omics to decode complex disease mechanisms and therapeutic responses.

Limitations and Transferability

While the study provides compelling mechanistic evidence, several limitations must be considered for broader translational relevance:

• Preclinical Scope: Findings are derived from murine models and immortalized cell lines; human validation is necessary for clinical translation.
• Complexity of Herbal Formulations: XXLP comprises hundreds of phytochemicals, complicating the attribution of effects to individual constituents or standardized doses.
• Microbiota Causality: While correlative, the causal direction between microbiota shifts and NOX2 suppression requires further mechanistic dissection.
• Omics Integration: Proteomic and metagenomic analyses are comprehensive but may overlook low-abundance mediators or context-specific interactions.

Despite these factors, the study’s multi-modal approach sets a methodological benchmark for future UC research and supports the rationale for integrative, multi-targeted therapies.

Research Support Resources

To facilitate studies on mitochondrial function and cellular ATP dynamics in inflammation or tissue injury models, researchers may consider the Luminescent ATP Detection Assay Kit (SKU: K2040) from APExBIO. This firefly luciferase ATP assay provides high-sensitivity quantification of ATP in cell and tissue samples, compatible with workflows assessing mitochondrial bioenergetics, oxidative stress, or downstream protein analysis. The kit’s simplified lysis protocol and broad linear range support robust, reproducible measurements in translational research contexts. For additional workflow guidance and troubleshooting advice, refer to internal resources detailing assay integration and sample compatibility.